Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372241 | 1.00 | YTHDC1 (0.51) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| Hydrochloric Acid SCHEMBL30335838 | 0.98 | YTHDC1 (0.50) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL17685339 | 0.92 | YTHDC1 (0.49) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL3376962 | 0.90 | YTHDC1 (0.58) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| Hydrochloric Acid SCHEMBL28453731 | 0.84 | YTHDC1 (0.43) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL13017781 | 0.84 | SLC6A2 (0.53) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| Hydrochloric Acid SCHEMBL5154522 | 0.83 | KDM4E (0.45) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL17685368 | 0.83 | CCR5 (0.43) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL17685375 | 0.83 | CCR5 (0.43) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL3373138 | 0.82 | SLC6A2 (0.51) | YTHDC1SLC6A2SLC6A4SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-10961218-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-3227275-B1 | CD38 INHIBITORS AND METHODS OF TREATMENT | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-9840496-B2 | CD38 inhibitors and methods of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| EP-3227275-A1 | CD38 INHIBITORS AND METHODS OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-02-02 | — | — | US | disclosed |
| US-20060014751-A1 | New 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-19 | — | — | US | disclosed |
| US-20060009457-A1 | New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | US | disclosed |
| EP-1599478-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2005-01-20 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2002051793-A1 | STEROL ISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009457-A1 | New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments | PLPBP, CYP2D6, CYP2B6 | YTHDC1 3266/4885SLC6A2 4209/4885SLC6A4 3532/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | YTHDC1 1784/4885SLC6A2 4231/4885SLC6A4 3398/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | YTHDC1 3307/4885SLC6A2 2543/4885SLC6A4 2703/4885 |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | YTHDC1 3213/4885SLC6A2 2220/4885SLC6A4 2408/4885 |
| US-10961218-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | YTHDC1 1717/4885SLC6A2 4651/4885SLC6A4 4763/4885 |
| US-20050014761-A1 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions | QDPR, DHPS, DHODH | YTHDC1 2219/4885SLC6A2 3989/4885SLC6A4 3126/4885 |
| US-20060014751-A1 | New 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments | FPR1, QDPR, FPR3 | YTHDC1 517/4885SLC6A2 1326/4885SLC6A4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.